Perilous to disagree with anyone here Brucy. But In fairness wildcat and co have put it out there, they are adamant offtake will be finalised soon which should in theory have funding solution followed very quickly. I said a year and half ago there way off when the other crowd were saying it should be done middle to end of 2017. And I have (not luckily) but with my knowledge of the region and problems faced - intelligently been proven right thus far. No I think listing on LSE will be delayed but will happen, I think offtake will be delayed, I think the share price will come under pressure. I think the next big mile stone for funding will be LSE listing where that market has an appetite for projects like dnk and the pockets for it as well. I think it was very clever and prudent that dnk have followed the management of kp2 going down that path remembering the kp2 management are bankers and finance people. Just my thoughts and there’s no need for anger against my thoughts because two things can happen here. It all clicks into place in the next 7 days and I’m wrong , or I’m luckily right again. And if I’m right again I need to get to the casino ASAP I’m right a lot .
Regards
- Forums
- ASX - By Stock
- DNK
- Ann: Full Year Statutory Accounts
Ann: Full Year Statutory Accounts, page-7
Featured News
Add DNK (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $151.0M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DNK (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online